AWHL · XBRL financial data

Aspira Women's Health financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AWHL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	2,217	2,130*	—	—	—	year only	0	169	89	32*	32	17
Revenue from contracts with customers	2,217	2,130*	2,153	2,423	2,257	2,349*	2,279	2,404	2,305	2,228*	1,967	2,046
Cost of goods and services sold	910	911*	939	1,002	902	860*	719	870	922	790*	896	915
Gross profit	1,307	—	1,214	1,421	1,355	—	1,560	1,534	1,383	—	1,071	1,131
Research and development	998	1,077*	906	952	908	500*	973	704	739	462*	1,226	692
General and administrative	2,723	2,534*	3,129	2,725	2,048	2,443*	2,741	1,961	1,540	1,722*	1,505	1,707
Total operating expenses	5,423	5,354*	5,924	5,814	5,099	4,920*	4,800	3,344	2,962	2,722*	3,274	2,966
Operating income (loss)	(4,116)	(4,135)*	(4,710)	(4,393)	(3,744)	(3,431)*	(3,240)	(1,810)	(1,579)	(1,284)*	(2,203)	(1,835)
Other income (expense)	599	(818)*	(165)	(16)	28	2,024*	1,508	(219)	1,009	(489)*	—	127
Net income (loss)	(4,706)	(3,089)*	(4,629)	(3,530)	(3,547)	(1,388)*	(1,853)	(2,666)	(4,892)	(3,369)*	676	(2,420)
Earnings per share, basic USD per share	(0.48)	(0.30)*	(0.39)	(0.28)	(0.23)	(0.08)*	(0.09)	(0.07)	(0.13)	(0.08)*	0.02	(0.05)
Earnings per share, diluted USD per share	(0.48)	(0.30)*	(0.39)	(0.28)	(0.23)	(0.08)*	(0.09)	(0.07)	(0.13)	(0.08)*	(0.05)	(0.05)
Weighted average shares, basic thousands of shares	9,776	10,414*	11,846	12,519	15,406	16,726*	21,591	35,564	36,388	42,612*	43,492	44,250
Weighted average shares, diluted thousands of shares	9,776	10,414*	11,846	12,519	15,406	16,726*	21,591	35,564	36,388	42,612*	45,774	44,250

Balance sheet

CSV

Fiscal quarters (AWHL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	5,100	2,597	3,413	962	2,133	1,769	3,312	1,545	3,809	1,755	1,344	477
Accounts receivable	1,590	1,459	1,531	1,445	1,254	990	1,100	1,278	1,317	1,207	1,424	1,485
Inventory	301	227	236	226	290	326	260	273	282	256	292	231
Prepaid and other current assets	581	997	942	618	436	1,098	719	590	417	845	725	603
Total current assets	7,572	5,280	6,122	3,251	4,113	4,183	5,391	3,686	5,825	4,063	3,785	2,796
Property and equipment, net	221	165	131	120	99	69	56	44	44	47	38	179
Right-of-use asset	600	528	620	559	515	1,194	1,142	1,077	1,029	980	931	880
Total assets	8,662	6,262	7,164	3,961	4,759	5,491	6,716	4,934	7,296	5,456	5,088	4,435
Accounts payable	1,382	1,261	1,643	1,943	2,551	2,173	1,451	1,743	1,811	1,237	1,968	2,753
Accrued liabilities	3,089	2,863	2,797	2,856	2,494	2,445	1,653	1,829	1,967	1,297	1,302	1,584
Current portion of long-term debt	378	166	249	316	229	229	231	232	234	236	238	199
Total current liabilities	5,162	5,119	5,293	5,458	5,466	5,468	3,791	4,098	4,199	3,465	5,595	5,338
Long-term debt	1,217	1,430	1,347	1,264	1,334	1,278	1,219	1,160	1,100	1,041	980	961
Lease liability, non-current	429	427	487	437	387	1,248	1,150	1,121	1,061	1,008	956	902
Total liabilities	9,321	8,627	8,527	7,670	7,279	8,054	6,776	7,619	11,640	12,388	11,295	11,691
Accumulated deficit	(515,214)	(518,303)	(522,932)	(526,462)	(530,009)	(531,397)	(533,250)	(535,916)	(540,808)	(544,177)	(543,501)	(545,921)
Total stockholders' equity	(659)	(2,365)	(1,363)	(3,709)	(2,520)	(2,563)	(60)	(2,685)	(4,344)	(6,932)	(6,207)	(7,256)
Total liabilities and equity	8,662	6,262	7,164	3,961	4,759	5,491	6,716	4,934	7,296	5,456	5,088	4,435
Common shares outstanding (cover page) thousands of shares	10,337	12,344	12,450	16,063	16,667	29,764	30,154	35,656	42,656	43,500	43,500	46,634

Cash flows

CSV

Fiscal quarters (AWHL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(4,706)	(3,089)*	(4,629)	(3,530)	(3,547)	(1,388)*	(1,853)	(2,666)	(4,892)	(3,369)*	676	(2,420)
Stock-based compensation	681*	422*	362	122*	380*	630*	103	16*	36*	376*	42	19*
Depreciation and amortization	40*	37*	29	26*	—	—	—	—	—	—	—	—
Net cash from operating activities	3,321	(3,450)*	(4,431)	(3,741)*	(2,920)*	(1,021)*	(3,102)	(1,734)*	(212)*	(1,981)*	(359)	(2,010)*
Purchases of property and equipment	0*	12*	20	15*	2*	0*	—	—	—	8*	—	—
Net cash from investing activities	0*	(12)*	(20)	(15)*	(2)*	0*	—	—	—	(8)*	—	—
Proceeds from issuing common stock	(9)*	0*	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	4,176*	961*	5,269	1,045*	4,093*	657*	4,645	(33)*	2,869*	(65)*	(52)	1,293*
Net change in cash	855*	(2,501)*	818	(2,711)*	1,171*	(364)*	1,543	(1,767)*	2,264*	(2,054)*	(411)	(867)*

Compare with peers

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aspira Women's Health	477	17	(2,010)*	46.6M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Creative Medical Technology Holdings	8,714	0	(1,472)*	6.6M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Target Group	14	1,381	(223)*	617.0M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Soligenix	9,811	not reported	(1,707)*	21.8M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Matinas BioPharma Holdings	761	not reported	(1,836)*	14.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Viskase Holdings	7,747	95,279	454*	14.3M	—	Q3 FY26 10-QSep 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026
China Pharma Holdings	305	948	(33)*	43.0M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Xenetic Biosciences	6,472	661	(875)*	2.3M	7.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.